Clinical Trial Update: Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of selumetinib in combination with cetuximab for refractory solid tumors has completed enrollment, including colorectal cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Rectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Status: COMPLETED